Immunic exercises exclusive IMU-856 global license option from Daiichi
Category: #health  By Mateen Dalal  Date: 2020-01-10
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Immunic exercises exclusive IMU-856 global license option from Daiichi

Immunic, a renowned biopharmaceutical company focused on treating autoimmune and chronic inflammatory diseases, reportedly announced that its subsidiary, Immunic AG, has implemented its exclusive global license option for a group of compounds that are designated by it as IMU-856.

The company exercised this option under the terms of its license agreement and existing option with Japanese pharmaceutical company, Daiichi Sankyo.

The company plans to initiate a phase 1 clinical trial for this novel program during the first half of 2020. The IMU-856 is a small molecule, orally available modulator that aims at a yet undisclosed protein that works like a transcriptional regulator for the intestinal barrier function.

IMU-856 signifies a novel and potentially disruptive method to treat intestinal diseases. the molecule also is capable of restoring the intestinal barrier function and it would also maintain immunocompetency.

President and Chief Executive Officer of Immunic, Daniel Vitt, Ph.D., stated that practicing this option is a vital milestone, as it signifies that the company is convinced about the IMU-856’s preclinical safety profile. Further, the company is ready to move ahead and take the program in phase 1 clinical studies, which it intends to start in the first half of 2020.  

Vitt further added that the company’s recently showcased preclinical information reinforced its belief that IMU-856 has disease-modifying features for several intestinal diseases and shows potential significant benefits on present immunosuppressive therapies which tackles inflammation while unintentionally reducing the immune surveillance of the body.

Vitt also added that the company is hopeful that this phase 1, multiple and single ascending dose trials would serve as a vital step for IMU-856’s development as a safe therapy option for patients with gastrointestinal diseases through restoring intestinal barrier function without impairing the patient’s immune system.

Senior Executive Officer and Global Head of R&D at Daiichi Sankyo, Junichi Koga stated that the company is pleased that Immunic exercised the option for IMU-856. The company is dedicated to providing innovative medicines to patients throughout the world as fast as possible, either by itself or from strategic partnerships.

Koga further added that the company is confident that Immunic is its best partner and would quickly propel the development of this new compound for patients suffering from intestinal diseases.

 

Source credit: https://www.immunic-therapeutics.com/2020/01/08/immunic-exercises-its-option-for-the-exclusive-worldwide-license-to-imu-856-from-daiichi-sankyo-co-ltd/

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Twitter introduces third-party signup, login support for Apple, Google

Twitter introduces third-party signup, login support for Apple, Google

By Mateen Dalal

The new feature eliminates the need to enter email and password to sign in. Signing in using your Apple ID is currently available only on iOS devices. Popular microblogging platform Twitter has reportedly introduced third-party login support to ...

Sony sells 10 million Play Station consoles just 294 days after launch

Sony sells 10 million Play Station consoles just 294 days after launch

By Mateen Dalal

Sony has reportedly managed to sell around 10 million Play Station 5 consoles in 249 days after its launch in November 2020. The company had sold approximately 7.8 million PS5 units as of April 2021. In comparison, approximately 10 million units of ...

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...